Herbal supplement (adaptogen)

Fadogia Agrestis

Fadogia agrestis testosterone data in the studies identified come from rats given a stem extract, and the app grades its evidence as anecdotal.1

Anecdotal evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Fadogia Agrestis after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.

Drawn from the half-life in the app's model, ~6 h. The model's figures

1

Overview

Fadogia agrestis is a plant of the family Rubiaceae, and the rat studies below used an aqueous extract of its stem.1 The University of Mississippi group that quantified its constituents in 2019 describes it as "used in traditional African medicine as an analgesic and for anti-inflammatory and aphrodisiac activities".2 The app files it as a supplement in the adaptogen group, with oral as its only route, and grades the evidence as anecdotal. No controlled trial in people was identified in PubMed or ClinicalTrials.gov, so the findings below are from rats unless a line says otherwise.

The 2005 rat study found alkaloids and saponins in the extract, with anthraquinones and flavonoids "weakly present", and its authors propose that a rise in testosterone "may be the mechanism responsible for its aphrodisiac effects and various masculine behaviors".1 A 2023 study by Ogunro and Yakubu in rats given paroxetine to induce erectile dysfunction concluded that the extract "restored the NO/cGMP pathway and ED-associated key enzymes in the penile and testicular tissues of male rats via antioxidant means".3 The 2009 liver and kidney study reports other evidence it describes as suggesting "disruption of the ordered lipid bilayer of the plasma membranes of the hepatocytes and nephrons", which its authors say "might have resulted from peroxidation of the polyunsaturated fatty acids on the membranes of the hepatocytes and nephrons".5 These are proposed mechanisms from rat tissue work; none was tested in people.

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~6 h
Bioavailability
50%
Typical dose
300–600 mg/day
Route
Oral
Time to peak
~2 h
Table 3.1Half-life and pharmacokinetics3 rows
ParameterApp's figureReported in the sources
Half-life~6 hNo half-life measurement for fadogia agrestis was identified in PubMed
Bioavailability50%No bioavailability measurement was identified in PubMed
Time to peak~2 hNo time-to-peak measurement was identified in PubMed

The app's half-life, bioavailability and time-to-peak figures are therefore shown without a source figure beside them, and no level chart is drawn.

4

Human studies

No controlled trial or other study of fadogia agrestis in people was identified in PubMed, ClinicalTrials.gov or the DailyMed label database. The rows below are the animal studies identified, in the same five-column layout, and each states that its animals are rats.

Studies in rats

Table 4.1Human studies4 rows
Study and yearDesignPeopleDose and lengthMain result
Yakubu and colleagues, Asian Journal of Andrology 20051Oral dosing study of the aqueous stem extract; sexual behaviour and serum testosterone measured1No people; male albino rats, number not given in the PubMed record118, 50 and 100 mg/kg body weight orally at 24 h intervals, measured on days 1, 3 and 51Serum testosterone rose in all dose groups "in a manner suggestive of dose-dependence"; mount and intromission frequency increased and ejaculatory latency was prolonged; no adverse events are reported in the PubMed record1
Yakubu and colleagues, Journal of Ethnopharmacology 20084Controlled dosing study with a 10-day recovery period; control group received 1 ml distilled water4No people; male rats (Rattus norvegicus), number not given in the PubMed record418, 50 and 100 mg/kg body weight orally every day for 28 days4Testicular cholesterol, sialic acid, glycogen and enzyme activities changed; the authors call the alterations "indications of adverse effects on the male rat testicular function", with some recovery mainly at 18 mg/kg4
Yakubu and colleagues, Human and Experimental Toxicology 20095Controlled dosing study of liver and kidney markers; control group received 1 mL distilled water5No people; male rats, number not given in the PubMed record518, 50 and 100 mg/kg body weight orally for 28 days5Liver and kidney enzyme activities fell with corresponding rises in serum, and serum malondialdehyde rose; no clinical toxicity symptoms and no mortality were recorded5
Ogunro and Yakubu, Reproductive Sciences 20233Controlled study in paroxetine-induced erectile dysfunction, with a sham control, a negative control and a sildenafil comparator3No people; 30 male Wistar rats in 6 groups of 53Extract at 18, 50 and 100 mg/kg body weight; sildenafil citrate 50 mg/kg; length of dosing not given in the PubMed record3Extract, like sildenafil citrate, raised penile and testicular NO, cGMP and antioxidant enzymes toward sham-control levels3

Deeper analysis: Yakubu and colleagues, 2005 (testosterone and sexual behaviour in rats)

Yakubu, Akanji and Oladiji, of the Medicinal Plants Research Laboratory, Department of Biochemistry, University of Ilorin, Nigeria, reported the study in the Asian Journal of Andrology in 2005.1 The stated aim was "to evaluate the phytochemical constituents and the aphrodisiac potential of the aqueous extract of Fadogia agrestis (Rubiaceae) stem in male albino rats".1 In the sexual behaviour measures, mount and intromission latency were reduced, and ejaculatory latency was prolonged, at the doses tested.1 The authors conclude that the extract "may be used to modify impaired sexual functions in animals, especially those arising from hypotestosteronemia".1 The PubMed record gives no group sizes, no testosterone values and no limitations section, and reports no adverse events or secondary results beyond those above.1 The record lists no grant or funder, and the affiliations given are university departments in Nigeria; the first and corresponding author, Yakubu, is also an author of the three later rat studies in this section.1,4,5,3

Deeper analysis: Yakubu and colleagues, 2008 (testicular indices after 28 days in rats)

The same Ilorin group reported in the Journal of Ethnopharmacology in 2008 that, compared with the control, the extract at the doses used gave "significant increase" in percentage testes-body weight ratio and in several testicular constituents.4 The same record lists decreases in "the activities of testicular alkaline phosphatase, acid phosphatase, glutamate dehydrogenase and concentrations of protein", so acid phosphatase appears in both the increased and decreased lists as printed.4 The authors write that the alterations "are indications of adverse effects on the male rat testicular function and this may adversely affect the functional capacities of the testes".4 They add that recovery at 18 mg/kg, "as used in folklore medicine suggests that it does not exhibit permanent toxicity at this dose".4 This sits beside the 2005 testosterone finding from the same group: a rise in serum testosterone over days 1 to 5 in the earlier study, and testicular changes the authors call adverse after 28 days in the later one.1,4 The PubMed record gives no group sizes, no limitations section and no funder.4

Deeper analysis: Yakubu and colleagues, 2009 (liver and kidney in rats)

Yakubu, Oladiji and Akanji reported in Human and Experimental Toxicology in 2009 a 28-day study of the extract at 18, 50 and 100 mg/kg in male rats against a distilled-water control.5 The record states that "Clinical toxicity symptoms such as respiratory distress, epistasis, salivation, hypo- and hyperactivity were not observed at any period of the experiment" and that no mortality was recorded.5 It also reports lower liver and kidney activities of alkaline phosphatase, lactate dehydrogenase and gamma glutamyl transferase with corresponding increases in serum, and higher serum malondialdehyde in all extract-treated groups.5 Organ weight ratios "compared well" with controls, and the extract "did not cause any swelling, atrophy or hypertrophy of the organs".5 The PubMed record carries the label "Research Support, Non-U.S. Gov't" and names no company sponsor; it gives no group sizes and no limitations section.5

Deeper analysis: Ogunro and Yakubu, 2023 (paroxetine-induced erectile dysfunction in rats)

Thirty male Wistar rats were split into six groups of five, with paroxetine-induced erectile dysfunction in groups II to VI, sildenafil citrate 50 mg/kg as the positive control and extract at 18, 50 and 100 mg/kg.3 The record says the extract, like sildenafil citrate, restored nitric oxide, cGMP and antioxidant enzyme levels "to levels that compared favourably" with the sham control.3 The record ends by stating that the study recommended the use of the extract in managing erectile dysfunction after clinical trials.3 The PubMed record gives no dosing length, no limitations section and no funder.3

5

Doses reported in studies and on labels

No DailyMed label giving a fadogia agrestis dose was returned, and no human dose was reported in the studies identified.

Table 5.1Doses reported in studies and on labels5 rows
SourceSpecies and routeDoseLength and comparator
App's figureNot stated300–600 mg/dayNot stated
Yakubu 20051Male rats, oral18, 50 and 100 mg/kg body weightDosed at 24 h intervals, measured on days 1, 3 and 5; comparator not described in the PubMed record
Yakubu 20084Male rats, oral18, 50 and 100 mg/kg body weightDaily for 28 days, then 10 days of recovery; control 1 ml distilled water
Yakubu 20095Male rats, oral18, 50 and 100 mg/kg body weight28 days; control 1 mL distilled water
Ogunro 20233Male Wistar rats, oral18, 50 and 100 mg/kg body weightLength not given in the PubMed record; sildenafil citrate 50 mg/kg comparator

The Mississippi analysis of 17 dietary supplements claiming to contain F. agrestis reported that "Twelve of 17 dietary supplements contained phenolic compounds in the range from 0.3 to 2.7 mg/d" and that the phenolic compounds were not detected in five.2 That 2019 Planta Medica work by Avula and colleagues at the National Center for Natural Products Research, University of Mississippi, was a chemistry method paper; its record lists an FDA grant (U01 FD004246) and states that the authors declare no conflicts of interest.2 It measured phenolic compounds in products and reports no testosterone or other measure in animals or people.2

6

Side effects reported

No adverse event report from people was identified in the sources searched. In rats given 18, 50 and 100 mg/kg for 28 days, the 2008 study reported what its authors call adverse effects on testicular function, and the 2009 study reported changes in liver and kidney enzyme activities and serum malondialdehyde with no recorded mortality.4,5

7

Bloodwork and markers

The app lists total testosterone, free testosterone and liver enzymes (ALT, AST) as markers to monitor. The 2005 rat study measured serum testosterone, and the 2009 rat study measured alkaline phosphatase, lactate dehydrogenase and gamma glutamyl transferase in liver, kidney and serum.1,5 The PubMed record for the 2009 study does not name ALT or AST, and no study measuring testosterone or liver markers in people was identified.5

8

Regulatory and anti-doping status

No fadogia agrestis label was returned by a DailyMed search, and no regulator assessment was retrieved. The WADA Prohibited List was not checked for the plant or its extract, so its anti-doping status is not stated here.

  • Whether fadogia agrestis changes testosterone in people: the testosterone finding in the sources identified is from a 2005 rat study, and no human study was identified.1
  • Its half-life, bioavailability and time to peak in any species, since no pharmacokinetic report was identified.
  • How the rat doses of 18 to 100 mg/kg relate to the app's 300–600 mg/day, since the studies identified do not link them.
  • Whether the rat testicular, liver and kidney changes occur in people, and whether other groups reproduce them: the four rat studies identified share the author Yakubu.4,5
  • The content of marketed products, which varied in the one analysis identified: phenolic compounds were not detected in five of 17 supplements.2
What is the half-life of fadogia agrestis?

The app lists a half-life of about 6 hours. No half-life measurement for fadogia agrestis was identified in PubMed, so no figure from a study sits beside the app's figure.

Has fadogia agrestis been tested in people?

No controlled trial in people was identified in PubMed or ClinicalTrials.gov. The studies identified used rats.

Does fadogia agrestis raise testosterone?

A 2005 study reported that an aqueous stem extract increased serum testosterone in male rats at 18, 50 and 100 mg/kg, in a manner "suggestive of dose-dependence".1 No measurement of testosterone in people was identified.

What is fadogia agrestis?

Fadogia agrestis is a plant of the family Rubiaceae used in traditional African medicine, according to the sources identified.1,2

What did rat studies report about fadogia agrestis and the liver?

A 2009 study in male rats reported lower liver and kidney activities of alkaline phosphatase, lactate dehydrogenase and gamma glutamyl transferase, with corresponding increases in serum, after 28 days.5 The same record reports no mortality and no clinical toxicity symptoms, and no liver study in people was identified.5 The same record also reports higher serum malondialdehyde in all extract-treated groups and describes other evidence as suggesting disruption of the plasma membranes of hepatocytes and nephrons.5

What did rat studies report about fadogia agrestis and the testes?

A 2008 study in male rats reported changes in testicular cholesterol, glycogen and enzyme activities after 28 days, which its authors call "indications of adverse effects on the male rat testicular function".4 The authors report recovery on some indices mainly at 18 mg/kg.4

Is there a drug label for fadogia agrestis?

No fadogia agrestis label was returned by a DailyMed search on 2026-11-16.

What evidence grade does the app give fadogia agrestis?

The app grades it as anecdotal, which is the app's grade and not a conclusion of the sources.

12

References

  1. Yakubu MT, Akanji MA, Oladiji AT. Aphrodisiac potentials of the aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male albino rats. Asian J Androl 2005;7(4):399-404. PMID 16281088
  2. Avula B, Bae JY, Raman V, et al. Quantification of Phenolic Compounds from Fadogia agrestis and Dietary Supplements using UHPLC-PDA-MS. Planta Med 2019;85(2):145-153. PMID 30170324
  3. Ogunro OB, Yakubu MT. Fadogia agrestis (Schweinf. Ex Hiern) stem extract restores selected biomolecules of erectile dysfunction in the testicular and penile tissues of paroxetine-treated Wistar rats. Reprod Sci 2023;30(2):690-700. PMID 35969364
  4. Yakubu MT, Akanji MA, Oladiji AT. Effects of oral administration of aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem on some testicular function indices of male rats. J Ethnopharmacol 2008;115(2):288-292. PMID 18023305
  5. Yakubu MT, Oladiji AT, Akanji MA. Mode of cellular toxicity of aqueous extract of Fadogia agrestis (Schweinf. Ex Hiern) stem in male rat liver and kidney. Hum Exp Toxicol 2009;28(8):469-478. PMID 19755438